Using multiple drugs to treat a single condition is growing, said Paul Zarkowski, MD, a clinical assistant professor at Harborview Medical Center and psychiatrist in Seattle, Washington, at Psych Congress 2018. But how much do we know about how well they work?
Using multiple drugs to treat a single condition is growing, said Paul Zarkowski, MD, a clinical assistant professor at Harborview Medical Center and psychiatrist in Seattle, Washington, at Psych Congress 2018. But how much do we know about how well they work?
In a presentation called “Doing More by Prescribing Less: Top Ten Drug Interactions That Limit Efficacy,” Zarkowski talked about why he is picking this topic to research.
“We’ve only got a few neurotransmitters, [like] serotonin, we’ve got lots of receptors, but we only have a few neurotransmitters to manipulate,” he said. “And if you start adding more and more meds, what happens is, you start blocking the actions of the other meds.”
Zarkowski said between 1996 and 2006, the average person went from 1 psychiatric medicine per indication to 2, according to one study. That goes for antidepressants, antipsychotics, and anti-anxiety medications, he noted.
There is not a lot of data about these drug combinations, Zarkowski said. Most trials are limited to 1 drug at a time.
“Whenever it comes time to study 2 at once, there’s crickets in the room,” he said, noting the hurdles such a study would pose in getting review board approval. However, there are uncertain gains for quality of care and clinical outcomes when these drugs are paired up, he said.
So Zarkowski decided to create his own list, using 3 criteria:
Zarkowski pulled the data from an electronic chart review from the Genoa Healthcare Database, which provides pharmacy services to behavioral health and addiction treatment communities, including the 10 community mental health organizations that released data about 12,488 patients.
The resulting top 10 list he came up with includes both approved and off-label uses.
Fluoxetine and cyproheptadine
Fluoxetine is indicated for the treatment of major depressive disorder (MDD) but it causes sexual dysfunction in about 36% of patients. Cyproheptadine is sometimes prescribed as an off-label use for anorgasmia caused by some selective serotonin reuptake inhibitors, but may cause depression to relapse.
A clinician could reduce the dose of fluoxetine or switch to an antidepressant with fewer sexual side effects, Zarkowski said. Another possibility is to add trazodone to an existing selective serotonin reuptake inhibitor.
Amitriptyline and naltrexone
Amitriptyline is indicated for depression and is sometimes used off-label for pain. Naltrexone is indicated for alcohol and opioid use disorder. In rat studies, naltrexone blocked the effect of amitriptyline. Naltrexone does not block every pain medication, however. And in one human case study, naltrexone caused depression to relapse.
Amphetamine-dextroamphetamine and haloperidol
Amphetamine-dextroamphetamine, an attention-deficit hyperactivity disorder (ADHD) medication, creates a drug-induced psychosis in 8% to 46% of regular users, depending on the dose, method, and duration. Haloperidol is used to counteract the psychosis. The interaction comes into play in internal “clock speed,” where amphetamine-dextroamphetamine speeds up processing, but haloperidol slows it down—unless the patient taking haloperidol has an affinity for the amphetamine-dextroamphetamine euphoria.
Donepezil and oxybutynin
Donepezil, a reversible acetylcholinesterase inhibitor, is indicated for Alzheimer disease, but 7% of patients will develop urinary incontinence. Oxybutynin is indicated for bladder muscle dysfunction, but it is associated with a decline in greater decline in mini-mental state examination scores over 2 years. Zarkowski said there are other medication choices that have fewer cognitive effects.
Amphetamine-dextroamphetamine and alprazolam
Amphetamine-dextroamphetamine can create anxiety in 8% of patients. Alprazolam is indicated for anxiety, but can cause sleepiness, memory impairment, and cognitive disorder. These 2 drugs have opposite effects on performance and also leads to a lessening in discriminative ability by people taking amphetamine. Studies from Europe have shown that the combination leads to more driving accidents.
Atomoxetine and propranolol
Atomoxetine, an ADHD drug, can increase heart rate and blood pressure. Propranolol, a hypertension drug, can impair learning performance.
Ropinirole and olanzapine
Ropinirole is indicated for restless leg syndrome (RLS), but can cause psychosis an 8% of Parkinson disease patients, or even in people taking it purely for RLS. There are case reports of olanzapine, used for schizophrenia, causing RLS. The drugs have opposite effects on the dopamine receptor.
Mirtazapine and clonidine
Clonidine is used off-label treatment for ADHD, but there are reports of MDD in up to about 2.3% of people taking it. Mirtazapine is an antidepressant, but causes sedation about half of the time. Mirtazapine blocks the alpha-2a receptor, but the clonidine stimulates it.
Clozapine and sertraline
Clozapine is indicated for schizophrenia, but it is linked to the emergence or worsening of obsessions, because it stimulates the receptor involved in OCD. Sertraline is indicated for obsessive compulsive disorder.
Venlafaxine and prazosin
Venlafaxine is indicated for MDD, which carries the risk of adverse side effect of nightmares (7% vs 2% on placebo). Prazosin is used off-label for nightmares and posttraumatic stress disorder (PTSD). Venlafaxine is not recommended for people with PTSD.
Clinician takeaways
Zarkowski said there are 3 things to keep in mind:
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More